Ufp Technologies IncUFPT

UFP Technologies Inc. is a contract development and manufacturing organisation that designs and makes customised single-use medical devices, sterile packaging, and engineered thermoplastic components for demanding markets like implants and diagnostics. The company’s latest acquisitions-Universal Plastics & Engineering Company, Inc. (“UNIPEC”) and Techno Plastics Industries (“TPI”)-are framed as a strategic leap into thin-film platforms and implantable applications, but the hard numbers tell a more pedestrian tale: UNIPEC clocks in at roughly $5 million in revenue and $2 million in EBITDA, a tidy tuck-in that barely registers against a $154.2 million top-line. The real headline is the inventory line, which now sits at $94 million and rose another $7.2 million in the March quarter. (source: UFP Technologies Acquires UNIPEC and TPI to Expand Film and Thermoplastic Molding Capabilities, https://ufpt.com/news/ufp-technologies-acquires-unipec-and-tpi-to-expand-film-and-thermoplastic-molding-capabilities/)

Put simply, UFP makes things for customers who do not tolerate failure: single-patient devices that must open cleanly the first time, sterile packaging that cannot breach, and components that go into the human body without apology. The company’s growth story leans on these mission-critical niches, but the numbers show a business that is still fighting the physics of working-capital absorption rather than coasting on the glory of mission statements. The Q1 filing reports $154.2 million in revenue and $17.5 million in net income, yet the cash machine is running at idle: net cash from operations was a meagre $3.2 million, and the company spent $5.7 million on new plant and equipment in the year-ago quarter. (source: UFP Technologies 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/914156/000208495626000050/000208495626000050.htm)

The company’s latest 10-Q shows $674.7 million in total assets against $235.8 million in liabilities, a sturdy equity base of $438.9 million, and a diluted share count of 7.8 million. Earnings per share landed at $2.24, a decent headline if the working-capital cycle weren’t quietly eating the cash. Research and development expense clocked $8.6 million for the year ending December 2025, a figure that looks less like aggressive innovation spend and more like the steady grind of staying compliant in a regulated sector. (source: UFP Technologies 10-Q and 10-K, https://www.sec.gov/Archives/edgar/data/914156/000208495626000050/000208495626000050.htm and https://www.sec.gov/Archives/edgar/data/914156/000091415625000108/000091415625000108.htm)

For those tracking the stock through TradingView or a broker terminal, the daily chart is merely a reflection of the underlying rhythm: a mid-cap industrial with a steady revenue base, modest EPS growth, and a balance sheet that is strong but not liquidity-rich. The company’s investor-relations calendar is busy-upcoming 1x1 meetings at the East Coast IDEAS conference and the CJS Securities New Ideas Summer Conference-where management will likely double down on the “comprehensive solutions” theme while the inventory line does the actual work of funding the next growth step. (source: UFP Technologies to Present and Host 1x1 Investor Meetings at the 16th Annual East Coast IDEAS Investor Conference, https://ufpt.com/news/ufp-technologies-to-present-and-host-1x1-investor-meetings-at-the-16th-annual-east-coast-ideas-investor-conference/; UFP Technologies, Inc. to Present and Host 1x1 Investor Meetings at the CJS Securities 26th Annual New Ideas Summer Conference, https://ufpt.com/news/ufp-technologies-inc-to-present-and-host-1x1-investor-meetings-at-the-cjs-securities-26th-annual-new-ideas-summer-conference/)

The company’s acquisition story is outwardly compelling: UNIPEC and TPI expand its thin-film platform and implantable capacity, but the filing evidence does not confirm any immediate step-change in revenue quality or margin uplift. The press releases are polished, the balance sheet is patient, and the investor conferences are booked. What remains unproven is whether the next tranche of growth can outrun the cash demands of inventory build and the modest EPS base. Until the company reports a step-change in operating cash flow or a clear reduction in inventory turns, the narrative will keep one foot on the accelerator and the other on the brake. (source: UFP Technologies SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=914156)